ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
The race for a coronavirus vaccine is one worldwide, but Asian countries face a host of challenges in developing one and are mostly trailing  efforts in the U.S. and Europe.
The global race for a coronavirus vaccine is on, but efforts in Asian countries are largely trailing those in the U.S. and Europe.   © Nikkei montage
Asia Insight

Japan's COVID vaccine sprint becomes marathon ahead of Olympics

From India to Thailand, nations seek homegrown shots as global death toll mounts

MITSURU OBE, Nikkei staff writer | Japan

OSAKA -- Japan's first clinical trial for a coronavirus vaccine is underway inside Osaka University Hospital. Some of the small-scale results, along with those from another university, are expected within the next month or so and will determine whether a larger trial can be held in November involving 500 people.

The project has attracted huge public attention and received financial support from the Japanese government. But whether the vaccine will receive approval and be manufactured on a significant enough scale in time for the Tokyo Olympic Games in July next year, remains a big question mark.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more